Cerapedics’ i-FACTOR P-15 Peptide Enhanced Bone Graft, a Trusted Choice in Bone Graft Solutions, Now Approved for Expanded Indications for Use
Find out moreCerapedics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Find out moreCerapedics Files Final Module of the PMA Application for FDA Approval of a new P-15 Peptide Enhanced Bone Graft for Lumbar Spine Fusion
Find out moreCerapedics Reinforces Commitment to Level 1 Evidence with Long-Term Results from Six-Year Pivotal IDE Cervical Study Demonstrating 98.6% Spine Fusion Rates in Patients Treated With i-FACTOR®
Find out moreCerapedics™ Announces Expansion of Headquarters to Support Growth of its Bone Graft Products
Find out moreCerapedics Appoints Valeska Schroeder Chairman and Chief Executive Officer
Find out moreCerapedics Completes Enrollment of Pivotal U.S. FDA IDE Study for its P-15L Bone Graft
Find out moreCerapedics Announces Publication of Results of Study Evaluating the Cost-Effectiveness of i-FACTOR vs. Local Autologous Bone in ACDF Surgery
Find out moreCerapedics Announces FDA Breakthrough Device Designation Granted for P-15L Bone Graft for the Treatment of Degenerative Disc Disease
Find out moreCerapedics Announces Commercial Launch of i-FACTOR®+ Matrix in Canada
Find out more
Welcome to Cerapedics
Choose your region
